TDOC Teladoc Health, Inc.
Services-Offices & Clinics of Doctors of Medicine · NYSE · SEC CIK 1477449 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.4%
TTM net income YoY30.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR-1.5%
Net income 3-yr CAGR—
Margins
Gross margin68.6%
Operating margin-6.6%
Net margin-6.3%
FCF margin10.6%
EBITDA margin—
Returns
ROE-11.5%
ROA-5.5%
ROIC (approx.)-23.2%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-8.00x
Cash quality & payout
Operating cash flow / net income-1.73x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $605.10M | $606.93M | $613.85M | $642.27M | $626.44M | $631.90M | $629.37M | $640.49M |
| Cost of revenue | $190.26M | $190.84M | $197.53M | $197.05M | $187.18M | $190.54M | $196.83M | $188.93M |
| Gross profit | $414.84M | $416.09M | $416.32M | $445.22M | $439.26M | $441.36M | $432.54M | $451.56M |
| R&D expense | $65.55M | $62.86M | $67.86M | $71.61M | $67.57M | $68.78M | $69.96M | $76.75M |
| SG&A expense | $107.40M | $104.03M | $102.09M | $108.42M | $102.58M | $108.11M | $112.77M | $100.00M |
| Operating income | -$28.10M | -$37.09M | -$61.77M | -$36.00M | -$51.96M | -$54.38M | -$120.61M | -$48.22M |
| Interest expense | $4.93M | $5.11M | $5.37M | $4.95M | $4.53M | $4.47M | $5.76M | $6.85M |
| Pretax income | -$26.28M | -$37.91M | -$60.84M | -$33.62M | -$50.22M | -$40.42M | -$111.27M | -$48.17M |
| Income tax | $655,000 | $997,000 | $3.00M | -$8.47M | -$715,000 | -$7.76M | -$18.25M | $238,000 |
| Net income | -$26.93M | -$38.91M | -$63.84M | -$25.14M | -$49.51M | -$32.66M | -$93.01M | -$48.41M |
| EPS (basic) | -0.15 | -0.21 | -0.36 | — | -0.28 | -0.19 | -0.53 | — |
| EPS (diluted) | -0.15 | -0.21 | -0.36 | — | -0.28 | -0.19 | -0.53 | — |
| Weighted avg. shares (diluted) | 181.88M | 181.03M | 179.12M | — | 176.93M | 175.92M | 174.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $849.91M | $774.35M | $750.74M | $781.08M | $726.25M | $679.62M | $1.19B | $1.30B |
| Receivables | $230.95M | $221.01M | $213.63M | $192.83M | $210.76M | $225.43M | $232.97M | $214.15M |
| Inventory | $30.75M | $28.82M | $31.56M | $38.20M | $39.90M | $38.16M | $38.01M | $38.14M |
| Current assets | $1.23B | $1.15B | $1.13B | $1.12B | $1.09B | $1.07B | $1.60B | $1.66B |
| PP&E, net | $24.41M | $24.69M | $26.28M | $26.97M | $26.92M | $27.67M | $30.64M | $29.49M |
| Goodwill | $283.19M | $283.19M | $283.19M | $283.19M | $283.19M | $283.19M | $283.19M | $283.19M |
| Intangibles | $1.12B | $1.18B | $1.24B | $1.30B | $1.34B | $1.38B | $1.39B | $1.43B |
| Total assets | $2.78B | $2.76B | $2.81B | $2.86B | $2.88B | $2.89B | $3.44B | $3.52B |
| Current liabilities | $1.42B | $1.38B | $404.87M | $404.74M | $405.09M | $401.77M | $952.42M | $941.53M |
| Total liabilities | $1.48B | $1.45B | $1.47B | $1.47B | $1.49B | $1.47B | $2.02B | $2.03B |
| Shareholders' equity | $1.29B | $1.31B | $1.34B | $1.39B | $1.39B | $1.42B | $1.43B | $1.49B |
| Shares outstanding | 182.25M | 181.65M | 180.43M | 178.32M | 177.35M | 176.61M | 175.34M | 173.41M |
| Cash flow statement | ||||||||
| Operating cash flow | $106.46M | $64.66M | $9.52M | $87.74M | $99.26M | $91.43M | $15.92M | $85.90M |
| Capital expenditure | $1.21M | $928,000 | $1.66M | $2.62M | $2.28M | $1.27M | $2.73M | $6.13M |
| Free cash flow | $105.24M | $63.73M | $7.86M | $85.12M | $96.98M | $90.16M | $13.19M | $79.77M |
| Investing cash flow | -$30.82M | -$41.59M | -$36.52M | -$34.32M | -$48.72M | -$59.70M | -$123.27M | -$29.64M |
| Financing cash flow | $417,000 | $875,000 | -$2.45M | $1.10M | -$3.59M | -$549.93M | $769,000 | $2.06M |
| Stock-based compensation | $11.62M | $9.30M | $14.61M | $15.91M | $17.00M | $22.34M | $25.16M | $27.47M |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.